Rationale, design and baseline patient characteristics of the optimal type 2 diabetes management including benchmarking and standard treatment study in Greece

doi:10.4239/wjd.v5.i1.76

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6010)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

386

WORD

237

HTML

2361

Figures (1-1)

249

Tables (1-5)

244

Sum=3477

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1173

Download

1360

Sum=2533

Feb 15, 2014 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Diabetes. Feb 15, 2014; 5(1): 76-83
Published online Feb 15, 2014. doi: 10.4239/wjd.v5.i1.76

Table 4 Treatment of the study population in Greece

Treatment	n (%)
Antidiabetic	740 (92.9)
Insulin	145 (19.6)
Biguanide (metformin)	519 (70.1)
Sulfonylurea	343 (46.4)
Glitazone	142 (19.2)
Others	104 (14.1)
Lipid-lowering	553 (69.4)
Statin	517 (93.5)
Ezetimibe	53 (9.6)
Fibrate	17 (3.1)
Others	43 (7.8)
Antihypertensive	591 (96.1¹)
ARBs	330 (55.8)
ACEi	202 (34.2)
CCBs	242 (40.9)
Beta-blockers	179 (30.3)
Alpha-blockers	13 (2.2)
Diuretics	220 (37.2)
Others	19 (3.2)
Anti-obesity	40 (5.0)
Aspirin	298 (37.4)

¹The percentage value refers to patients with hypertension. ARBs: Angiotensin receptor blockers; ACEi: Angiotensin converting enzyme Inhibitors; CCBs: Calcium channel blockers.

Citation: Kostapanos MS, Tsimihodimos V, Elisaf MS, Tzouvelekis E, Nikas N. Rationale, design and baseline patient characteristics of the optimal type 2 diabetes management including benchmarking and standard treatment study in Greece. World J Diabetes 2014; 5(1): 76-83
URL: https://www.wjgnet.com/1948-9358/full/v5/i1/76.htm
DOI: https://dx.doi.org/10.4239/wjd.v5.i1.76